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Endovascular vs. Open Repair for Abdominal Aortic Aneurysm: Systematic Review and Meta-analysis 
of Updated Peri-operative and Long Term Data of Randomised Controlled Trials 
Objectives 
The objective was to investigate whether endovascular aneurysm repair (EVAR) has better peri -
operative and late clinical outcomes than open repair for non-ruptured abdominal aortic aneurysm. 
 
Methods 
Electronic bibliographic sources (MEDLINE, EMBASE, and CENTRAL) were searched up to July 2019 
using a combination of thesaurus and free text terms to identify randomised controlled trials (RCTs) 
comparing the outcomes of EVAR and open repair. The systematic review was conducted according 
to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Pooled 
estimates of dichotomous outcomes were calculated using odds ratio (OR) or risk difference (RD) 
and 95% confidence interval (CI). A time to event data meta-analysis was performed using the 
inverse variance method and the results were reported as summary hazard ratio (HR) and 95% CI.  
 
Results 
Seven RCTs reporting a total of 2 983 patients were included in quantitative synthesis. Three of the 
trials reported long term follow up that extended to 15.8 years, 14.2 years, and 12.5 years. Meta-
analysis found significantly lower odds of 30 day (OR, 0.36; 95% CI 0.20–0.66) and in hospital 
mortality with EVAR (RD –0.03; 95% CI –0.04 to −0.02). Meta-analysis of the three trials reporting 
long term follow up found no significant difference in all cause mortality at any time between EVAR 
and open repair (HR 1.02; 95% CI 0.93–1.13; p = .62). The hazard of all cause (HR 0.62; 95% CI 0.42–
0.91) and aneurysm related death within six months (HR 0.42; 95% CI 0.24–0.75) was significantly 
lower in patients who underwent EVAR, but with further follow up, the pooled hazard estimate 
moved in favour of open surgery; in the long term (>8 years) the hazard of aneurysm related 
mortality was significantly higher after EVAR (HR 5.12; 95% CI 1.59–16.44). The risk of secondary 
intervention (HR 2.13; 95% CI 1.69–2.68), aneurysm rupture (OR, 5.08; 95% CI 1.11–23.31), and 
death due to rupture (OR, 3.57; 95% CI 1.87–6.80) was significantly higher after EVAR, but the risk of 




Compared with open surgery, EVAR results in a better outcome during the first six months but 
carries an increased risk of aneurysm related mortality after eight years. 
 
What this paper adds 
Following the recent National Institute for Health and Care Excellence draft guidance proposing that 
patients should not be offered endovascular aneurysm repair (EVAR) if open surgical repair is 
suitable, long term data of randomised controlled trials, with follow up of up to 15 years, have been 
published. This review is the first to include the most updated data and use time to event meta-
analytical methods. Significantly lower odds of peri-operative mortality were confirmed with EVAR. 
The hazard of all cause and aneurysm related death within six months of surgery was si gnificantly 
lower after EVAR, but with further follow up the pooled hazard estimate moved in favour of open 
surgery; in the long term (>8 years), the hazard of aneurysm related mortality was significantly 
higher in patients who underwent EVAR. The risk of secondary intervention, aneurysm rupture, and 
death due to rupture was significantly higher after EVAR, but there was no significant difference in 




Abdominal aortic aneurysm (AAA) repair is a major component of vascular service provision. The 
prevalence of AAA in men 65 years of age attending the Swedish nationwide AAA screening 
programme in a contemporary setting was 1.5%.1 After a mean of 4.5 years, 29% of patients had 
surgery for AAA, with a 30 day mortality of 0.9%.1 Despite the application of national screening 
programmes in several countries, AAA remains a significant healthcare burden across the world with 
a considerable associated mortality. In a large Swedish registry based cohort study, the AAA 
mortality was 36 deaths per 100 000 men aged 65–74 years in the early 2000s dropping to 10 deaths 
per 100 000 men of the same age in 2015.2 
 
The past couple of decades have witnessed the advent and evolution of endovascular aneurysm 
repair (EVAR), which has become an established less invasive treatment with a marked improvement 
in peri-operative morbidity, mortality, and recovery compared with traditional surgery. From 2009 
to 2013, an increase was observed in the proportion of repairs being performed as endovascu lar 
procedures in the UK (54% in 2009 rising to 66% in 2013), and this trend has stabilised over the last 
few years, with EVAR procedures accounting for 68% of the elective infrarenal AAA repairs in 2017.3 
However, recent studies have shown that the early survival benefit of EVAR decreases or is even lost 
over time, with EVAR carrying a higher risk of rupture and secondary intervention than open surgical 
repair in the long term.4,5 As a result, the UK's National Institute for Health and Care Excellence 
(NICE) issued a draft guidance on AAA diagnosis and management with the notable recommendation 
that patients should not be offered EVAR if open surgical repair is suitable.6 This recommendation 
has led to much debate around the optimal treatment of unruptured AAA and has cast a shadow 
over the potential benefits of EVAR. 
 
Long term results of randomised controlled trials (RCTs) with follow up of up to 15 years have been 
published recently.5,7,8 In view of the absence of a systematic review and meta-analysis of the most 
updated long term outcome data and the global ongoing controversy over the potential benefits of 
EVAR, a meta-analysis was undertaken of published high quality long term data of EVAR vs. open 
surgical repair for unruptured AAA. Such analysis will produce more precise and powerful outcome 
estimates than the individual RCTs and help inform decision making. 
 
Objectives 
The objective was to investigate whether EVAR has better peri -operative and late clinical outcomes 




The objectives and methodology of the review were pre-specified in a protocol. The review was 
conducted and reported in accordance with the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines.9 
 
Criteria for considering studies for this review 
Types of studies 
RCTs comparing outcomes of EVAR vs. open repair in patients with unruptured infrarenal AAA.  
 
Types of participants 
Male or female patients of any age who were diagnosed with AAA and underwent elective standard 
EVAR or open repair. Patients with symptomatic or ruptured AAA and those who required complex 
endovascular procedures for the treatment of AAA were not included.  
 
Types of interventions 
• 
Intervention of interest: EVAR 
 
• 
Control intervention: open aneurysm repair 
 
 
Types of outcome measures 
Primary outcomes 
• 
30 day and in hospital mortality 
 
• 
All cause mortality 
 
• 













death due to aneurysm rupture 
 
• 
death due to malignancy 
 
 
Search methods for identification of studies 
The literature search strategy was developed by the review author team in collaboration with a 
clinical information specialist. Studies related to the subject were identified by searching electronic 
information sources and bibliographic reference lists of relevant articles. 
 
Electronic searches 
The Healthcare Databases Advanced Search (HDAS) interface developed by the NICE was used to 
interrogate the following electronic bibliographic databases: the National Library of Medicine's 
database (MEDLINE), Excerpta Medica Database (EMBASE), and the Cochrane Register of Studies 
(CRS) (CENTRAL). A combination of controlled vocabulary (thesaurus) and free text terms was used 
to search the databases. No language constraints were applied. The literature search was last run in 
July 2019. The search strategy is presented in Appendix 1. 
 
Searching other resources 
The bibliographic lists of the selected trials were screened for additional studies.  
 
Study selection and data collection 
Selection of studies 
Two review authors (G.A., S.A.) conducted the pre-specified literature searches and evaluated the 
eligibility of studies for inclusion independently. When disagreement arose, a third review author 
(F.T.) acted as arbitrator. 
 
Data extraction and management 
One review author (G.A.) extracted data from selected studies. The collected data were then cross 
checked by a second review author (S.A.). Retrieved data were entered into a spreadsheet. Only 
published material was considered. The following types of data were extracted from the selected 
studies: 
• 
study related data 
 
• 
data related to risk of bias assessment 
 
• 
demographics and clinical characteristics of the study populations 
 
• 






Assessment of risk of bias in included studies 
The risk of bias tool developed by the Cochrane Collaboration was used to assess the risk of bias of 
selected RCTs.10 The risk of bias assessment was performed independently by two review authors 
(G.A., S.A.). A third review author acted as adjudicator in the event of disagreement (F.T.). 
Furthermore, a summary of findings table was generated and the quality of evidence was graded 
using the system developed by the Grades of Recommendation, Assessment, Development and 
Evaluation (GRADE) working group applying an online platform (https://gdt.gradepro.org/app/).11 
 
Data analysis 
Measures of treatment effect 
Pooled estimates of dichotomous outcome data were calculated using the odds ratio (OR) and 95% 
confidence interval (CI). If one or more studies reported zero events in both groups, the risk 
difference (RD) and 95% CI were calculated instead. A meta-analysis of time to event data was 
conducted using the inverse variance method and the result was reported as summary hazard ratio 
(HR) and 95% CI. A mixture of direct (e.g. from reported HRs with CI) and indirect methods was 
applied (e.g. from survival curves with or without numbers at risk) to calculate the individual study 
HR and standard error (SE) for specific outcome measures.12 Data extracted from published Kaplan–
Meier curves were digitised using the open source software Plot Digitizer 
(http://plotdigitizer.sourceforge.net). If the incidence rate ratio, calculated by (events/person time) 
group 1/(events/person time) group 2 was reported by the studies, it was used as an approximation 
to HR. For the additional outcomes (aneurysm rupture, death due to aneurysm rupture and death 
due to malignancy), the studies provided no sufficient data for time to event meta-analysis; 
therefore, those variables were analysed as dichotomous data and the summary OR and 95% CI was 
calculated. 
 
Unit of analysis issues 
The individual patient. 
 
Dealing with missing data 
No attempt was made to contact the primary authors enquiring about missing data.  
 
Assessment of heterogeneity 
Between study heterogeneity was examined with the Cochrane's Q (χ2) test. Inconsistency was 
quantified by calculating I2 and was interpreted it using the following guide: 0%–40% might not be 
important; 30%–60% may represent moderate heterogeneity; 50%–90% may represent substantial 
heterogeneity; and 75%–100% may represent considerable heterogeneity.10 
 
Assessment of reporting biases 
It was planned to visually assess the symmetry of funnel plots and perform the Egger's test if more 
than 10 studies were identified. 
 
Data synthesis 
Fixed effect models were applied, unless significant statistical heterogeneity was present (p < .050 
and I2≥75%), in which case random effects meta-analysis was conducted. A forest plot was created 
for each treatment effect. 
 
Subgroup analysis and investigation of heterogeneity 
No subgroup analysis was undertaken. 
 
Sensitivity analysis 
One trial at a time was excluded and analysis for each of the primary and secondary outcomes was 
repeated. Trials that were judged to be of high risk of bias in two or more domains were excluded 
and the analyses were repeated. Studies with short or medium term follow up (<8 years) were also 
excluded from time to event data meta-analyses. 
 
Results 
Results of the search 
After discarding irrelevant reports and excluding articles with reasons, the literature search 
identified seven RCTs in 18 publications that fulfilled the inclusion criteria (Fig. 1).5,7,8,13, 14, 15, 
16, 17, 18, 19, 20, 21, 22, 23, 24 Reports on cost effectiveness, quality of life and post hoc analysis, 
and those published as a conference abstract were not considered. A protocol in a peer reviewed 
journal was found for three of these trials.25, 26, 27 One of the trials was published in Chinese.21 
 
Figure 1 
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Figure 1. Study flow diagram using the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) template for randomised controlled trials comparing endovascular vs. open 
repair for abdominal aortic aneurysm. *Duplicates were not removed using the Healthcare 
Databases Advanced Search (HDAS) interface since database specific thesaurus terms were used. 
EVAR = endovascular aneurysm repair; RCT = randomised controlled trial.  
 
Description of studies 
The trials reported a total of 2983 patients, 1518 of whom underwent EVAR and the remaining 1465 
open repair. Four of these trials were large multicentre studies that were conducted in five different 
countries: the UK (EVAR-1, 37 centres), The Netherlands (DREAM, 26 centres), Belgium (DREAM, four 
centres), France (ACE, 25 centres), and the USA (OVER, 42 centres). The remaining three trials were 
smaller trials conducted in China,21 Canada,22 and The Netherlands.23,24 The recruitment period 
spanned from 1999 to 2011, and the follow up ranged from 30 days to a median of 12.4 years. Three 
of the trials (EVAR-1, OVER, and DREAM) reported long term follow up that extended up to 15.8 
years, 14.2 years, and 12.5 years, respectively. These trials conducted an additional analysis of 
extended follow up that ended in June 2015 in the EVAR-1 trial,5 December 2016 in the OVER trial,7 
and January 2016 in the DREAM trial.8 The study characteristics are presented in Table 1, the 
inclusion and exclusion criteria for patient enrolment in Table S1, and the baseline demographics 
and clinical characteristics of the study populations in Table S2. Notably, EVAR-1 randomised older 
patients with larger AAA than the other trials. 
 
 
Risk of bias in included studies 
In general, the study quality was high. One or more outcomes of interest in the review (aneurysm 
related mortality and secondary interventions) were not reported or reported incompletely in four 
of the trials (ACE, OVER, Chen et al.,21 Soulez et al.22), so they could not be entered in a meta-
analysis, thus these trials were judged to be high risk of bias in the selective reporting domain of the 
Cochrane tool. For the rest of the domains, the risk of bias was judged to be low or unclear. The risk 
of bias graph and summary are presented in Fig. 2, and the supports for judgement are presented in 
Appendix 2. 
 
Effects of interventions 
Primary outcomes 
Thirty day mortality was reported by four studies (EVAR-1, OVER, ACE, Lottman et al.;23,24 total of 
1265 patients in the EVAR group and 1207 patients in the open repair group). It was 1.2% after EVAR 
and 3.1% after open repair, thus significantly lower in patients who underwent EVAR (OR, 0.36; 95% 
CI 0.20–0.66; p = .001). The statistical heterogeneity was not significant (p = .31, I2 = 17%). Similarly, 
in hospital mortality, reported by five studies (EVAR-1, OVER, DREAM, Chen et al.,21 Soulez et al.;22 
total of 1297 patients in the EVAR group and 1269 patients in the open repair group), was 1.4% after 
EVAR and 4.5% after open repair, thus significantly lower in patients that underwent EVAR (RD –
0.03; 95% CI –0.04 to −0.02; p < .001). The statistical heterogeneity was negligible (p = .58, I2 = 0%) 
(Fig. 3). 
 
Meta-analysis of the three trials reporting long term follow up (EVAR-1, OVER, DREAM) with a total 
of 2484 patients found no significant difference in all cause mortality at any time between EVAR and 
open repair (HR 1.02; 95% CI 0.93–1.13; p = .62), with negligible statistical heterogeneity (p = .56, I2 
= 0%). All cause mortality within six months from surgery was significantly lower after EVAR than 
after open repair (HR 0.62; 95% CI 0.42–0.91; p = .010), whereas the difference became non-
significant at longer intervals post-AAA treatment (Fig. 4). 
 
 
Meta-analysis of two trials (EVAR-1, DREAM) with a total of 1603 patients found no significant 
difference in aneurysm related mortality at any time between EVAR and open repair (HR 1.11; 95% 
CI 0.78–1.59; p = .55), and the statistical between study heterogeneity was moderate (p = .19; I2 = 
43%). Interestingly, meta-analysis of aneurysm related mortality at different time intervals following 
treatment showed that the pooled estimate within six months was in favour of EVAR (HR 0.42; 95% 
CI 0.24–0.75; p = .003), whereas as the interval from the treatment lengthened, the pooled HR 




Two studies (EVAR-1, DREAM) with a total of 1603 patients reported data on re-intervention in long 
term follow up. Meta-analysis of these trials found a significantly higher hazard of re-intervention 
with EVAR than with open surgical repair (HR 2.13; 95% CI 1.69–2.68; p < .001), and the statistical 
heterogeneity was moderate (p = .15; I2 = 51%) (Fig. 6). 
Additional outcomes 
Two trials (OVER, DREAM) with a total of 1232 patients reported data on aneurysm rupture in long 
term follow up. Meta-analysis showed that the odds of rupture was significantly higher in EVAR (OR, 
5.08; 95% CI 1.11–23.31; p = .040) with an insignificant statistical heterogeneity (p = .61, I2 = 0%) 
(Fig. S1). 
Deaths secondary to aneurysm rupture or cancer were reported in all three trials reporting long 
term follow up (EVAR-1, OVER, DREAM) with a total of 2484 patients. Meta-analysis found that the 
odds of death due to rupture was significantly higher after EVAR than after open repair (OR, 3.57; 
95% CI 1.87–6.80; p < .001), and the statistical heterogeneity was moderate (p = .11, I2 = 55%). The 
odds of death due to cancer was not significantly different between EVAR and open repair (OR, 1.03; 
95% CI 0.84–1.25; p = .80) with low statistical heterogeneity (p = .45; I2 = 0%) (Fig. S1). 
Sensitivity analysis 
The differences in all cause mortality at six months (HR 0.70; 95% CI 0.38–1.31; p = .27) and the 
aneurysm related mortality at > 8 years (HR 2.78; 95% CI 0.08–100.01; p = .58) became insignificant 
when the EVAR-1 trial was excluded from the analysis. Furthermore, the difference in the odds of 
death due to rupture became insignificant when the EVAR-1 trial was removed (OR, 1.57; 95% CI 
0.60–4.07; p = .36). The difference in the odds of rupture became insignificant when the DREAM trial 
was removed (OR, 6.98; 95% CI 0.86–57.00; p = .070). 
Discussion 
Summary of main results 
Meta-analysis of RCT data found significantly lower odds of peri -operative (in hospital and 30 day) 
mortality with EVAR than with open repair. Meta-analysis of long term follow up data showed that 
the hazard of all cause and aneurysm related death at any time following intervention was not 
significantly different between EVAR and open repair. An interesting finding was that the hazard of 
all cause and aneurysm related death within six months from surgery was significantly lower in 
patients who underwent EVAR, but with longer follow up, the pooled hazard estimate moved in 
favour of open surgery and, in the long term (>8 years), the difference in hazard of aneurysm related 
mortality was significantly lower in patients who underwent open repair. Notably, these differences 
were driven by the results of the EVAR-1 trial, which recruited older patients with larger AAAs. The 
hazard of secondary intervention, aneurysm rupture, and death due to rupture was significantly 
higher after EVAR, but the risk of death due to cancer was not significantly different between EVAR 
and open surgical repair. 
 
Overall completeness and applicability of evidence 
All seven RCTs directly investigated the review question, i.e. whether EVAR has better clinical 
outcomes than open surgery for unruptured AAA. One trial provided 30 day data only and focused 
the analysis on health related quality of life after EVAR and open repair.23 Aneurysm related 
mortality, which is the most important outcome to assess the comparative efficacy of EVAR and 
open repair, was reported by two trials only (EVAR-1 and DREAM). The selected trials applied broad 
inclusion criteria for patient enrolment and were conducted in four European countries, the USA, 
Canada, and China, representing practices across the developed world. Eligible patients had 
aneurysm morphology suitable for standard EVAR and were considered physiologically fit for open 
surgical repair. In the OVER trial, the authors explicitly stated that patients had to meet the 
manufacturer's indications for the endovascular system that would be used if so assigned. One 
would argue that anatomical suitability for EVAR spreads across a wide spectrum of morphological 
parameters, thus outcomes of patients lying at the border of anatomical suitability are unknown. 
Furthermore, the trials were conducted more than a decade ago, when newer generation aortic 
devices, sophisticated EVAR planning software, and modern radiology equipment were not available, 
which would limit the applicability of the review findings in current practices. Furthermore, the 
accumulated experience of surgery, radiology, and operating theatre staff as well as the efficient 
coordination between team members might confer different outcomes in contemporary practice. 
Very few women were recruited in the trials hence the results may not be generalisable to female 
patients. 
 
Quality of the evidence 
A small number of RCTs reporting a total of a few thousand patients have been conducted to 
investigate comparative clinical outcomes of EVAR and open repair for unruptured AAA. Three of the 
trials (EVAR-1, OVER, DREAM) reported long follow up of a median of 12.7, 10.2, and 9.4 years, 
respectively. Another two studies (ACE and Soulez et al.22) reported medium term follow up of a 
mean of around two and a half years, whereas Chen et al.21 reported short term follow up and 
Lottman et al.23,24 presented 30 day data only. Because there was evidence that the HR for the 
primary outcomes (all cause and aneurysm related mortality) did not remain constant over the full 
10 years, the ACE and Soulez et al.22 trials were not included in the meta-analysis of time to event 
data. 
 
The largest study, which dominated the meta-analysis outcomes, was the EVAR-1 with 1252 
patients. This is evident in sensitivity analyses, which showed that the pooled estimate for all cause 
mortality at six months, aneurysm related mortality >8 years, and death due to rupture changed 
when the EVAR-1 trial was excluded from the meta-analysis. This finding may be explained by the 
fact that EVAR-1 enrolled older patients with larger aneurysms, which have been shown to be poor 
prognostic indicators following EVAR.28 One could argue that in the presence of such a small 
number of trials, the lack of statistical significance in sensitivity analyses is probably due to lack of 
precision. 
 
The key methodological constrain was selective reporting in four trials (OVER, ACE, Soulez et al.22 
and Chen et al.21), which did not report data for the key outcome of interest in this review 
(aneurysm related mortality). Consistency of the results across the trials was noted, which is 
reflected in the low or moderate heterogeneity for all outcomes. The overall quality of the body of 
evidence contributing to the results of the review was high. The certainty in the meta-analysis 
findings was judged to be high or moderate for all primary and secondary outcomes (Table 2).  
 
Potential biases in the review process 
The review was conducted in accordance with the PRISMA guidelines and every effort was made to 
mitigate bias. The review is strengthened by a vigorous search of the literature to identify all 
relevant studies and obtain all relevant data. However, no attempt was made to contact the authors 
for missing data. 
 
Agreements and disagreements with other studies or reviews 
A few systematic reviews on long term outcomes of EVAR vs. open repair have been published 
recently, none of which have included the most updated data of the OVER trial.29, 30, 31 Notably, 
previous reviews failed to identify three randomised clinical trials investigating comparative 
outcomes of EVAR and open aneurysm repair. Furthermore, none of the previously published 
reviews conducted meta-analysis of aneurysm related mortality at different time intervals from the 
index procedure and meta-analysis of deaths due to rupture or cancer in the long term. Those 
reviews are also flawed by mixing randomised clinical trials and observational studies in meta-
analysis models, a practice that is not recommended,10 and are dominated by observational rather 
high quality randomised data. They are also limited by the fact that they performed analysis of time 
to event outcome data (e.g. all cause mortality or re-intervention) as a binary response variable, 
which is not an optimal meta-analytical strategy because ignoring censored observations is 
inefficient.32 
 
An individual patient data meta-analysis of the four RCTs with a median follow up of 5.5 years found 
that within three years, the survival curves of patients who underwent EVAR and open repair 
converged and beyond three years, aneurysm related mortality was significantly higher in the EVAR 
group.33 This review was conducted three years ago, when long term follow up data up to 15 years 
were not available. 
 
The results of the analysis are corroborated by findings of large administrative registries 
investigating comparative outcomes of endovascular vs. open repair for intact AAA. A large study of 
health insurance claims data in Germany found that in hospital mortality was lower following EVAR 
than after open repair and a trend toward lower long term survival after EVAR.34 Similarly, in 
propensity score matched cohorts of Medicare beneficiaries, EVAR compared with open repair was 
associated with a substantial early survival advantage that gradually decreased over time, with the 
rate of late rupture being significantly higher after endovascular repair than after open repair.35 It 
should be noted that none of those registries provided data on very long follow up extending up to 
15 years. 
 
The review findings are reflected in the quality of life following surgery for AAA. The DREAM study 
group found less severe disruption to health related quality of life and health status in the short 
term in patients who underwent EVAR. However, during longer term follow up, patients who were 
treated by open repair appeared to have improved quality of life and health status.36 
 
There have been concerns previously expressed about the increased cancer risk related to exposure 
to external radiation from the procedure and/or surveillance with computed tomography.37 Such 
concerns that patients undergoing EVAR are at increased risk of developing abdominal cancer 
compared with those undergoing open repair are not reflected in the results of the quantitative 
synthesis, which found similar risks of death from any cause or cancer after EVAR and open repair.  
 
Conclusions 
Implications for practice 
The meta-analysis demonstrated that EVAR carries a lower peri-operative and early (within six 
months) mortality risk than open surgical repair for unruptured infrarenal AAA. The long term 
aneurysm related mortality, re-intervention and rupture rates are higher after EVAR than after open 
repair, and patients who develop rupture following EVAR are more likely to die than those whose 
aneurysm ruptures after open repair. Interpreted in the context of an ever increasing life 
expectancy, the findings reinforce the European Society for Vascular Surgery guidelines, which 
recommend open repair for patients with reasonable prospects of long term survival.38 In contrast, 
those with shorter life expectancy are likely to benefit from EVAR rather than open repair, 
particularly if their surgical risk is higher than average. In individual patients, clinicians should thus 
base their recommendations on the perceived risk of AAA rupture, life expectancy, and surgical risk. 
However, the differences in outcome between open repair and EVAR appear more qualitative than 
quantitative, with patients who undergo open surgery taking the bulk of the AAA and intervention 
related risk upfront (in the peri-operative period), and those undergoing EVAR distributing this risk 
over their lifetimes. Individual patients’ culture, prejudices, personality, and personal circumstances 
may thus lead them to view the prospect of undergoing either treatment from different perspectives 
to that of the clinician (or healthcare provider) during the shared decision making process. Some 
patients, for example, may value early survival more than freedom from late complications, and may 
thus legitimately choose EVAR over open repair, even if appropriately counselled.  
 
Implications for research 
It remains uncertain which individual patients would benefit from EVAR and which from open repair 
based on their physiological status. Personalised or precision medicine applying medical models 
where interventions for AAA treatment are tailored to the individual patient based on their 
predicted response or risk is an unexplored field in AAA disease. 
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Figure 1. Study flow diagram using the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) template for randomised controlled trials comparing endovascular vs. open 
repair for abdominal aortic aneurysm. *Duplicates were not removed using the Healthcare 
Databases Advanced Search (HDAS) interface since database specific thesaurus terms were used. 
EVAR = endovascular aneurysm repair; RCT = randomised controlled trial.
 
  
Figure 2. (A) Risk of bias graph: review authors' judgements about each risk of bias item presented as 
percentages across all included studies combining endovascular vs. open repair for abdominal ao rtic 




Figure 3. Forest plots of 30 day and in hospital mortality in patients treated by endovascular vs. open 
repair for abdominal aortic aneurysm. The solid squares denote the odds ratios (ORs) or risk 
differences (RDs), the horizontal lines represent the 95% confidence intervals, and the diamonds 




Figure 4. Forest plots of all cause mortality in patients treated by endovascular vs. open repair of 
abdominal aortic aneurysm. The solid squares denote the hazard ratios (HRs), the horizontal lines 
represent the 95% confidence intervals, and the diamonds denote the pooled HRs. CI = confidence 
interval; EVAR = endovascular aneurysm repair; IV = inverse variance; SE = standard error.
 
Figure 5. Forest plots of aneurysm related mortality in patients treated by endovascular vs. open 
repair of abdominal aortic aneurysm. The solid squares denote the hazard ratios (HRs), the 
horizontal lines represent the 95% confidence intervals, and the diamonds denote the pooled HRs. CI 
= confidence interval; EVAR = endovascular aneurysm repair; IV = inverse variance; SE = standard 
error. 
 
  
 
 
